Last reviewed · How we verify
NCT06555640
A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
Phase 2 trial testing DR10624 Injection in Severe Hypertriglyceridemia in 79 participants. Completed in 29 August 2025.
30 June 2025
Quick facts
| Lead sponsor | Zhejiang Doer Biologics Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 79 |
| Start date | 1 August 2024 |
| Primary completion | 30 June 2025 |
| Estimated completion | 29 August 2025 |
| Sites | 35 locations across China |
Drugs / interventions tested
- DR10624 Injection — full drug profile →
- Placebo
Conditions studied
- Severe Hypertriglyceridemia — all drugs for Severe Hypertriglyceridemia →
Sponsor
Zhejiang Doer Biologics Co., Ltd. — full company profile →
Who can join
Adults 17 to 75, any sex, with Severe Hypertriglyceridemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
DR10624 is an Fc fusion protein tri-agonist with balanced glucagon-like peptide-1 receptor (GLP-1R)/glucagon receptor (GCGR)/ fibroblast growth factor 21 receptor (FGF21R) agonizing activities. The objectives of the planned clinical investigation will be to evaluate the efficacy of DR10624 on fasting serum triglyceride (TG) levels after 12 weeks of treatment in subjects with severe hypertriglyceridemia (SHTG).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Triple Agonism Based Therapies for Obesity.
Goldney J, Hamza M, Surti F, Davies MJ, et al · · 2025 · cited 5× · PMID 40741227 · DOI 10.1007/s12170-025-00770-z
Verify or expand the search:
- PubMed search for NCT06555640
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DR10624 Injection
Trials testing the same drug.
- NCT07024212 — Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects · Phase 2 · active not recruiting
Other Zhejiang Doer Biologics Co., Ltd. trials
Trials by the same sponsor.
- NCT07024212 — Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects · Phase 2 · active not recruiting
- NCT07056777 — Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastr · Phase 1, PHASE2 · recruiting
- NCT06132828 — Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
- NCT05378893 — A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624 · Phase 1 · completed
- NCT05639153 — A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Adva · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06555640 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Doer Biologics Co., Ltd.
- Last refreshed: 13 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06555640.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing